Mohammed Hannan, MD
Internal Medicine · Fayetteville, NCNPI 1417906520
Payments from drug & device makers
Across 382 payments — averaging $15.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$770
- GSK$618
- Novo Nordisk$591
- Boehringer Ingelheim$519
- AstraZeneca$442
- Bayer$418
- plus $2K from 33 others
What the payments were for
- Food & beverage$5,844100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 50 | $770 |
| GSK | 48 | $618 |
| Novo Nordisk | 38 | $591 |
| Boehringer Ingelheim | 33 | $519 |
| AstraZeneca | 28 | $442 |
| Bayer | 27 | $418 |
| Pfizer | 19 | $313 |
| Johnson & Johnson | 16 | $232 |
| Amgen | 17 | $220 |
| Amarin Pharma, Inc. | 12 | $183 |
| Novartis | 9 | $158 |
| Radius Health, Inc. | 8 | $146 |
| Sanofi-aventis U.S. LLC | 7 | $122 |
| Exact Sciences | 6 | $115 |
| Sunovion Pharmaceuticals Inc. | 10 | $107 |
| Abbott | 6 | $92 |
| AbbVie(2 entities) | 6 | $90 |
| Inspire Medical Systems, Inc. | 1 | $85 |
| Merck | 6 | $77 |
| Sumitomo Pharma America, Inc. | 5 | $66 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $47 |
| Medtronic(2 entities) | 2 | $41 |
| Esperion Therapeutics, Inc. | 2 | $38 |
| Azurity Pharmaceuticals, Inc. | 2 | $37 |
| Kowa Pharmaceuticals America, Inc. | 3 | $36 |
| Ironwood Pharmaceuticals, Inc | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Boston Scientific | 2 | $24 |
| Si-bone, Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| Alvogen Inc | 1 | $15 |
| Seqirus USA Inc | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Baxter Healthcare | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Eisai Inc. | 1 | $11 |
How this compares
$5,844 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 134 | $137,552 |
| OzempicSemaglutide | 67 | $92,954 |
| EliquisApixaban | 84 | $92,276 |
| RybelsusSemaglutide | 54 | $88,280 |
| FarxigaDapagliflozin Propanediol | 55 | $59,116 |
| LinzessLinaclotide | 49 | $57,516 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $53,751 |
| TrulicityDulaglutide | 20 | $43,018 |
| XareltoRivaroxaban | 16 | $24,415 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 14 | $23,483 |
| EntrestoSacubitril/Valsartan | 19 | $22,357 |
| JanuviaSitagliptin Phosphate | 20 | $21,990 |
| MounjaroTirzepatide | 18 | $18,756 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 14 | $15,658 |
| TradjentaLinagliptin | 21 | $15,439 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $591 | $181,234121 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $519 | $176,473169 claims |
| PfizerEliquis, Abrysvo, Premarin | $313 | $101,346117 claims |
| AstraZenecaFarxiga, Symbicort | $442 | $64,85870 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $770 | $61,77438 claims |
| GSKTrelegy Ellipta, Shingrix | $618 | $57,65270 claims |
| AbbVieLinzess | $90 | $57,51649 claims |
| MerckJanuvia, Janumet Xr | $77 | $37,64934 claims |
| Johnson & JohnsonXarelto | $232 | $24,41516 claims |
| NovartisEntresto | $158 | $22,35719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Fayetteville
- Nitin DesaiFayetteville$6.4M
- Daniel UbaFayetteville$1.2M
- Eugene WrightFayetteville$839K
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- John RubinoRaleigh$13M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.